HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $25 Price Target

HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on ORIC Pharmaceuticals (NASDAQ: ORIC) and maintained a price target of $25 for the stock.